Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma 3Neoplasms 3Brain Neoplasms 3Thyroid Carcinoma, Anaplastic 2Sarcoma, Synovial 2Prostatic Neoplasms 2Neurofibrosarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Gliosarcoma 2Glioblastoma 2Dermatofibrosarcoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Somatostatinoma 1Solid Neoplasm 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Recurrent Uterine Corpus Sarcoma 1Recurrent Lymphoepithelioma of the Nasopharynx 1Pheochromocytoma 1Perivascular Epithelioid Cell Neoplasms 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Ovarian Neoplasms 1

Interventions

pazopanib 1ixabepilone 1Thalidomide 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Recurrent Uterine Corpus Sarcoma × pazopanib × Clear all
NCT01247571 2019-08-08

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 8 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡